Pharm
Tenofovir
search
Tenofovir
, Tenofovir Disoproxil, TDF, Tenofovir Alafenamide, TAF, Viread
See Also
Anti-Retroviral Therapy
Nucleoside Reverse Transcriptase Inhibitor
Preparations
Tenofovir Disoproxil Fumarate (TDF)
Original Tenofovir formulation and used in Stribild,
Truvada
and Complera
Associated with nephrotoxicity and decreased
Bone Mineral Density
Tenofovir Alafenamide Fumarate (TAF)
Tenofovir formulation released in 2016 and used in Genvoya,
Descovy
, Odefsey
TAF appears to have less adverse
Renal Function
and
Bone Mineral Density
effects than the original TDF
TAF is associated with greater weight gain and dyslipidemia than TDF
Mechanism
Nucleoside Reverse Transcriptase Inhibitor
Adverse Effects
See
nRTI
for adverse effects attributed to the class
Renal dysfunction
Increased
Serum Creatinine
Proteinuria
Electrolyte
abnormalities
Glycosuria
Hypophosphatemia
Acute Renal Failure
(1% risk)
Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
Gastrointestinal
Diarrhea
Nausea
or
Vomiting
Flatulence
Miscellaneous
Headache
Hepatitis B
flares on withdrawal of medication
Dosing
Dose: 300 mg orally daily
Monitoring
Obtain
Urinalysis
every 6 months when on Tenofovir Disoproxil Fumarate
Obtain baseline
Renal Function
and
Phosphorus
, then at 2-8 weeks, and then every 3-6 months
References
(2016) Presc Lett 23(9)
(2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Type your search phrase here